Related references
Note: Only part of the references are listed.Leveraging Surface Plasmon Resonance to Dissect the Interfacial Properties of Nanoparticles: Implications for Tissue Binding and Tumor Penetration
Aniket S. Wadajkar et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2019)
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Alice Lee et al.
CANCER TREATMENT REVIEWS (2018)
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
Sheheryar Kabraji et al.
CLINICAL CANCER RESEARCH (2018)
Focus on Fundamentals: Achieving Effective Nanoparticle Targeting
Gregory T. Tietjen et al.
TRENDS IN MOLECULAR MEDICINE (2018)
Protein corona: a new approach for nanomedicine design
Van Hong Nguyen et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas
Aniket S. Wadajkar et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer
Chunsheng He et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
Yu-Cheng Su et al.
NATURE COMMUNICATIONS (2017)
Predictive and Prognostic Brain Metastases assessment in luminal Breast cancer Patients: Fn14 and grP94 from Diagnosis to Prophylaxis
Antonio Martinez-Aranda et al.
FRONTIERS IN ONCOLOGY (2017)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
Novel Strategy Utilizing Extracellular Cysteine-Rich Domain of Membrane Receptor for Constructing D-Peptide Mediated Targeted Drug Delivery Systems: A Case Study on Fn14
Zhuoxuan Li et al.
BIOCONJUGATE CHEMISTRY (2017)
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics
J. G. Perez et al.
ONCOGENE (2016)
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Jung Soo Suk et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue
Jimena G. Dancy et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Breast cancer brain metastases: biology and new clinical perspectives
Isabell Witzel et al.
BREAST CANCER RESEARCH (2016)
Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy
Rammohan Devulapally et al.
ACS NANO (2015)
Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells
Craig S. Schneider et al.
BIOMATERIALS (2015)
Emerging Strategies for Treating Brain Metastases from Breast Cancer
David P. Kodack et al.
CANCER CELL (2015)
Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle
Erik C. Dreaden et al.
CLINICAL CANCER RESEARCH (2015)
Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeutics
Craig S. Schneider et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Elvin Blanco et al.
NATURE BIOTECHNOLOGY (2015)
A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models
Jayanta Bhattacharyya et al.
NATURE COMMUNICATIONS (2015)
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Madappa Kundranda et al.
Drug Design Development and Therapy (2015)
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells
Hsueh-Te Lee et al.
ONCOTARGET (2015)
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Nicolas Bertrand et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models
John Do et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Paclitaxel-loaded PCL-TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane®
Ezequiel Bernabeu et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2014)
Regulation of Fibroblast Growth Factor-inducible 14 ( Fn14) Expression Levels via Ligand-independent Lysosomal Degradation
Sujatha Gurunathan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Development of HumanSerine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC
Hong Zhou et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts
Ludmilla de Plater et al.
PLOS ONE (2014)
Targeted Therapy for Breast Cancer
Ali Mohamed et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
Joyce O'Shaughnessy et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Antitumor Activity of a Humanized, Bivalent Immunotoxin Targeting Fn14-Positive Solid Tumors
Hong Zhou et al.
CANCER RESEARCH (2013)
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies
Valentina Guarneri et al.
DRUGS (2013)
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb
Debra T. Chao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment
Hong Zhou et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface
Anna Salvati et al.
NATURE NANOTECHNOLOGY (2013)
Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
Carey K. Anders et al.
PLOS ONE (2013)
TWEAK/Fn14 axis-targeted therapeutics: moving basic science discoveries to the clinic
Emily Cheng et al.
FRONTIERS IN IMMUNOLOGY (2013)
Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2- Primary Breast Tumors
Rebeca Sanz-Pamplona et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman et al.
CLINICAL CANCER RESEARCH (2010)
Targeting of drugs and nanoparticles to tumors
Erkki Ruoslahti et al.
JOURNAL OF CELL BIOLOGY (2010)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Kazuki N. Sugahara et al.
CANCER CELL (2009)
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Farrah Kassam et al.
CLINICAL BREAST CANCER (2009)
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts
Andrew Baschnagel et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting of albumin-embedded paclitaxel nanoparticles to tumors
Priya Prakash Karmali et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2009)
The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity
Amanda L. Willis et al.
MOLECULAR CANCER RESEARCH (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The TWEAK - Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting
Jeffrey A. Winkles
NATURE REVIEWS DRUG DISCOVERY (2008)
Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome
Nhan L. Tran et al.
CANCER RESEARCH (2006)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
DE Owens et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies
M Nakayama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids
WM Li et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro
T Yoneda et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Share Paper
